John Sheridan

President, CEO, and Director at TANDEM DIABETES CARE

Board

Since March 2019

Age

68 years

Education

Holds a B.S. in Chemistry from the University of West Florida and an MBA from Boston University.

Tenure

Joined TNDM as Executive Vice President and Chief Operating Officer in April 2013, was promoted to President and CEO in March 2019, and has served on the board of directors since June 2019.

Also at TANDEM DIABETES CARE

Elizabeth Gasser

Executive Vice President and Chief Strategy and Product Officer

James Leal

Chief Manufacturing Officer

Jean-Claude Kyrillos

Executive Vice President and Chief Operating Officer

About

John Sheridan has built an extensive career in healthcare and technology, having held several key leadership positions prior to joining TNDM. He served in pivotal roles at firms such as Rapiscan Systems, Volcano Corporation, CardioNet (now BioTelemetry), and Digirad Corporation, showcasing his wide-ranging expertise in operations and research & development.

Throughout his career, his focus on innovation and operational excellence has been evident, as he has successfully steered multiple organizations through periods of transformation. His strategic insights and leadership have contributed to advancements in medical technology and systems, reflecting his commitment to the industries he has served.

At TNDM, his impactful journey began in April 2013 when he took on the role of Executive Vice President and Chief Operating Officer. His subsequent promotion in March 2019 to President and CEO, along with being appointed to the board of directors in June 2019, underscores his significant contribution in shaping the company’s direction and growth.

Beyond his role at TNDM, his participation on the board of directors of another company highlights his broader industry influence. His professional narrative not only reveals a strong foundation in operational leadership but also a consistent drive to enhance healthcare technology through innovation and strategic vision.

$TNDM Performance Under John Sheridan

Past Roles

Organization	Role	Date Range	Details
Tandem Diabetes Care	Executive Vice President and Chief Operating Officer	April 2013 – March 2019	Previous role at TNDM prior to becoming CEO
Rapiscan Systems, Inc.	Chief Operating Officer	March 2012 – February 2013	Provider of security equipment and systems
Volcano Corporation	Executive Vice President, Research and Development and Operations	November 2004 – March 2010	Medical technology company
CardioNet, Inc. (now BioTelemetry, Inc.)	Executive Vice President of Operations	May 2002 – May 2004	Medical technology company
Digirad Corporation	Vice President of Operations	March 1998 – May 2002	Medical imaging company

External Roles

Organization	Role	Date Range	Details
Acutus Medical, Inc.	Director	Since March 2021	Arrhythmia management company board role

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$710,700	Annual	Fixed annual amount provided for core responsibilities; unchanged from 2022 as no salary increases were applied
All Other Compensation	$11,140	Annual	Includes Group Term Life Insurance Premiums of $4,540 and 401(k) Employer Contributions of $6,600; Other expenses not applicable

Performance Compensation

Data from FY 2023

Cash Bonus Plan

Component	Weight (%)	Threshold Payout (% of Target Bonus)	Target Payout (% of Target Bonus)	Maximum Payout (% of Target Bonus)	Actual Achievement/Payout	Payout Amount (USD)	Payment Conditions/Vesting	Evaluation Period
Financial Performance	80	50% (at 90% revenue target reached)	100% (at revenue target reached)	200% (at ≥110% revenue target)	0% (threshold not met)	$0	One-time annual incentive; no vesting	2023
Product Development	10	50% (upon meeting minimum product launches)	100% (target launches)	200% (with outperformance)	200% (4 new products launched)	Contributed 20% to total bonus	One-time annual incentive; no vesting	2023
Customer Satisfaction	10	50% (upon meeting customer satisfaction metrics)	100% (target scores)	200% (with outperformance)	175%	Contributed 17.5% to total bonus	One-time annual incentive; no vesting	2023
Total / Overall	100	N/A	N/A	N/A	37.5% Total Payout	$266,513 (based on base salary of $710,700)	One-time annual cash bonus; based on annual performance	2023

Long-Term Incentive (LTI) Equity Compensation Program

Metric/Component	Details/Value	Conditions/Vesting Details	Evaluation Period
Revenue CAGR Objective	Weight: 30%; Payout Factor: 50% at threshold, 100% at target, 200% at maximum	Based on 3-year performance (2023–2025); linear interpolation applied between levels	2023–2025
TSR (Total Shareholder Return) Objective	Weight: 20%; Payout Factor: 50% at threshold, 100% at target, 200% at maximum	Comparison against the Russell 3000 Index; performance measured over the same 3-year period; linear interpolation applied	2023–2025
Performance Stock Units (PSUs)	65,659 units; Aggregate Value: $1,726,175	Vesting contingent on achieving performance metrics; payout occurs in 2026; subject to continued employment	2023–2025 (vesting in 2026)
Restricted Stock Units (RSUs)	65,659 units; Aggregate Value: $1,726,175	Vesting over a 36-month period: 33% vests on May 25, 2024, and the remaining 67% vests in quarterly installments over the next 24 months; subject to continued employment	2023–2025 (vesting starting 2024)
Grant Details	Grant Date: May 25, 2023; Grant Date Fair Value: $26.29 per share	No explicit grant date stock price provided; valuation based on the fair value per share	2023

These tables provide a comprehensive breakdown of John Sheridan's 2023 performance compensation, covering both the short-term cash bonus plan and the long-term equity compensation components with all available metrics, targets, thresholds, weights, vesting details, and actual payout outcomes where applicable.